Trial in progress: QUINTESSENTIAL-2-a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
Lebel, E. Abdulgawad, A. Bramanti, S. Garate, G. Ho, P. J. Keränen, M. Cohen, Y. Vase, M. Khot, A. Kristensen, I. B.
Lebel, E.
Abdulgawad, A.
Bramanti, S.
Garate, G.
Ho, P. J.
Keränen, M.
Cohen, Y.
Vase, M.
Khot, A.
Kristensen, I. B.
Abstract
Authors
Lebel, E.
Abdulgawad, A.
Bramanti, S.
Garate, G.
Ho, P. J.
Keränen, M.
Cohen, Y.
Vase, M.
Khot, A.
Kristensen, I. B.
Leblanc, R.
Lee, C.
Legiec, W.
Magen, H.
Mateos, M. V.
Oh, D.
Pour, L.
Schutz, N.
Spyridonidis, A.
Weisel, K.
Zaucha, J.
Larson, S.
Varshasvsky, A.
Grazioli, K.
Basudhar, D.
Hu, H. X.
Meng, Y.
Eldjerou, L.
Bal, S.
Harrison, S.
Popat, R.
Raab, M.
Rodriguez-Otero, P.
Abdulgawad, A.
Bramanti, S.
Garate, G.
Ho, P. J.
Keränen, M.
Cohen, Y.
Vase, M.
Khot, A.
Kristensen, I. B.
Leblanc, R.
Lee, C.
Legiec, W.
Magen, H.
Mateos, M. V.
Oh, D.
Pour, L.
Schutz, N.
Spyridonidis, A.
Weisel, K.
Zaucha, J.
Larson, S.
Varshasvsky, A.
Grazioli, K.
Basudhar, D.
Hu, H. X.
Meng, Y.
Eldjerou, L.
Bal, S.
Harrison, S.
Popat, R.
Raab, M.
Rodriguez-Otero, P.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Lebel E, Abdulgawad A, Bramanti S, Garate G, Ho PJ, Keränen M, et al. Trial in progress: QUINTESSENTIAL-2-a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide. Blood. 2025 NOV 3;146:2302-3.